The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior Treatment With Sunitinib or a Cytokine: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, and VEGFR-3. Based on the positive opinion from the European Medicines Agency (EMA), a marketing authorization valid throughout the European Union (EU) was issued for the treatment of advance...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Oncologist
Main Authors: Tzogani, Kyriaki, Skibeli, Venke, Westgaard, Ingunn, Dalhus, Marianne, Thoresen, Hege, Slot, Karsten Bruins, Damkier, Per, Hofland, Kenneth, Borregaard, Jeanett, Ersbøll, Jens, Salmonson, Tomas, Pieters, Ronny, Sylvester, Richard, Mickisch, Gerald, Bergh, Jonas, Pignatti, Francesco
Formáid: Artigo
Teanga:Inglês
Foilsithe: AlphaMed Press 2015
Ábhair:
Regulatory Issues: EMA
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319625/
https://ncbi.nlm.nih.gov/pubmed/25616431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0177
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla